

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL STUDY OF ICP-332 FOR THE TREATMENT OF ATOPIC DERMATITIS MET PRIMARY ENDPOINT

This announcement is made by InnoCare Pharma Limited (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce the positive top-line results from the phase II randomized, double-blind, placebo-controlled study of ICP-332, an once-daily oral inhibitor of TYK-2, in adult patients with moderate-to-severe atopic dermatitis (the “**AD**”).

As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway in T cells, playing an important role in the pathogenesis of inflammatory diseases. ICP-332 is a potent and selective TYK-2 inhibitor with about 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors.

The phase II study is a randomized, double-blind, placebo-controlled trial evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of ICP-332 in moderate-to-severe atopic dermatitis.

Patients with AD treated with ICP-332 for 4 weeks showed excellent efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints including Eczema Area and Severity Index (“**EASI**”) 50, EASI 75, EASI 90 (improvement of at least 50%, 75%, and 90% in EASI score from baseline) and Investigator’s Global Assessment (IGA) 0/1 (score of 0 [clear] or 1 [almost clear]) in ICP-332 80mg and/or 120mg group respectively.

The mean percentage change from baseline in the EASI score, a measure of the eczema area and severity of atopic dermatitis, reached to 78.2% at 80mg once-daily dosing with a highly significant P value ($p < 0.0001$) and 72.5% at 120mg once-daily dosing with a highly significant P value ($p < 0.0001$) compared to 16.7% for patients receiving placebo. EASI 75 reached to 64%/64% at 80mg and 120mg dosing respectively, compared to 8% percent for patients receiving placebo ($p < 0.0001$).

In this study, all treatment-related adverse events (TRAEs) were mild or moderate, which is comparable to those from receiving placebo.

The Company will continue to evaluate the potential of ICP-332 in phase III of atopic dermatitis and across multiple immune-mediated diseases.

ICP-332 is an investigational oral agent and is not approved by regulatory authorities. We cannot guarantee that we will ultimately develop or commercialize ICP-332 successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 17 December 2023

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu, Dr. Kaixian Chen Dr.Dandan Dong as independent non-executive Directors.